PMID- 15522471
OWN - NLM
STAT- MEDLINE
DCOM- 20050303
LR  - 20211203
IS  - 0195-668X (Print)
IS  - 0195-668X (Linking)
VI  - 25
IP  - 21
DP  - 2004 Nov
TI  - Effect of candesartan on New York Heart Association functional class. Results of 
      the Candesartan in Heart failure: Assessment of Reduction in Mortality and 
      morbidity (CHARM) programme.
PG  - 1920-6
AB  - AIMS: To evaluate the effect of the angiotensin receptor blocker candesartan on 
      New York Heart Association (NYHA) functional class in a broad spectrum of 
      patients with chronic heart failure (CHF). METHODS AND RESULTS: Patients in the 
      CHARM Programme with symptomatic CHF were randomized to placebo (n=3796) or 
      candesartan (n=3803) and followed for a median of 38 months. NYHA class was 
      assessed at baseline, at two weekly intervals during dose titration and 4 monthly 
      thereafter. Patients were classified as "better", "unchanged" or "worse" at the 
      end of the study compared to baseline. Both a simple "last visit carried forward" 
      (LVCF) analysis and "worst rank carried forward" (WRCF) analysis (where patients 
      who died were allocated NYHA class V) were used. In the LVCF analysis, compared 
      to placebo, more candesartan patients improved (35.4% versus 32.5%) and fewer 
      worsened (9.0% versus 10.3%) in NYHA class (p=0.003). The WRCF analysis also 
      showed a better overall change in NYHA class with candesartan compared to 
      placebo. There was no heterogeneity in the response to candesartan between the 
      CHARM component trials. CONCLUSIONS: Candesartan improves NYHA functional class 
      to a similar extent to other proven treatments for CHF when added to these other 
      treatments.
FAU - O'Meara, Eileen
AU  - O'Meara E
AD  - Department of Cardiology, Western Infirmary, Glasgow, Scotland, UK.
FAU - Solomon, Scott
AU  - Solomon S
FAU - McMurray, John
AU  - McMurray J
FAU - Pfeffer, Marc
AU  - Pfeffer M
FAU - Yusuf, Salim
AU  - Yusuf S
FAU - Michelson, Eric
AU  - Michelson E
FAU - Granger, Chris
AU  - Granger C
FAU - Olofsson, Bertil
AU  - Olofsson B
FAU - Young, James B
AU  - Young JB
FAU - Swedberg, Karl
AU  - Swedberg K
LA  - eng
PT  - Clinical Trial
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
PL  - England
TA  - Eur Heart J
JT  - European heart journal
JID - 8006263
RN  - 0 (Angiotensin-Converting Enzyme Inhibitors)
RN  - 0 (Benzimidazoles)
RN  - 0 (Biphenyl Compounds)
RN  - 0 (Tetrazoles)
RN  - S8Q36MD2XX (candesartan)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Angiotensin-Converting Enzyme Inhibitors/*therapeutic use
MH  - Benzimidazoles/*therapeutic use
MH  - Biphenyl Compounds
MH  - Female
MH  - Heart Failure/*drug therapy/mortality
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Tetrazoles/*therapeutic use
MH  - Treatment Outcome
EDAT- 2004/11/04 09:00
MHDA- 2005/03/04 09:00
CRDT- 2004/11/04 09:00
PHST- 2004/03/25 00:00 [received]
PHST- 2004/07/08 00:00 [revised]
PHST- 2004/07/15 00:00 [accepted]
PHST- 2004/11/04 09:00 [pubmed]
PHST- 2005/03/04 09:00 [medline]
PHST- 2004/11/04 09:00 [entrez]
AID - S0195-668X(04)00510-X [pii]
AID - 10.1016/j.ehj.2004.07.025 [doi]
PST - ppublish
SO  - Eur Heart J. 2004 Nov;25(21):1920-6. doi: 10.1016/j.ehj.2004.07.025.